European Companies Search Engine

EU funding (€22.9M): RISK assessment of chemicals integrating HUman centric Next generation Testing strategies promoting the 3Rs Hor28 Jan 2021 EU Research and Innovation programme "Horizon"

Overview

Text

RISK assessment of chemicals integrating HUman centric Next generation Testing strategies promoting the 3Rs

The vision of the RISK-HUNT3R consortium is to develop a reliable, efficient and cost-effective chemical safety assessment approach. It will be based entirely on non-animal methods and provide improved protection of the human population against systemic health effects caused by (chronic) chemical exposure. The major innovation provided by RISK-HUNT3R is a complete and truly human-centric risk assessment strategy. RISK-HUNT3R will establish, optimize and assemble all essential safety testing elements: exposure assessment, information on chemical distribution in the body, hazard characterization, adverse outcome prediction and determination of actual risk in defined scenarios. RISK-HUNT3R integrates cutting-edge in silico (computational) and in vitro (experimental testing) technologies. Human (disease) genetics and exposome data will ensure anchoring of test results to the human situation. The project will ensure regulatory relevance by testing the applicability of the critical test systems integrated in the next generation risk assessment strategy. The ambitious overall deliverable will be a comprehensive computational framework for the prediction of human adverse outcomes, and a set of stringently evaluated assays to feed the required data into this framework. RISK-HUNT3R will engage with all key stakeholders from different industry sectors and international regulatory agencies to critically evaluate and warrant genuine acceptance of the novel safety testing framework. This unique interaction of these key stakeholders working together on real-world case studies, will result in a ready-to-apply strategy to ensure societal protection against hazardous chemicals fully in concordance with the European Commission’s “Green Deal”. Importantly, the project will push commercial exploitation of the validated safety assessment approaches, thereby ensuring sustainability of the project outcomes and fortifying the innovation capacity of the industry sectors involved.


Funded Companies:

Company name Funding amount
Basf Metabolome Solutions GmbH €0.00
Basf SE €626,875
Bayer SAS €16,805.00
Bioclavis Ltd. €2,012,231
BioDetection Systems B.V. €582,500
Bundesinstitut Fuer Risikobewertung €842,363
Certara UK Ltd. €725,625
Charles River Laboratoiries DEN Bosch B.V. €7,500.00
Cosmetics Europe - THE Personal Care Association €0.00
Danmarks Tekniske Universitet €260,348
Edelweiss Connect GmbH €939,043
European Molecular Biology Laboratory €318,411
Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. €970,750
Industria de Diseno Textil SA €5,000.00
Insphero AG €100,000
Institut National de la Sante et de la Recherche Medicale €400,000
Karolinska Institutet €353,200
Katholieke Universiteit Leuven €800,000
Kobenhavns Universitet €400,091
L'Oreal SA €15,000.00
Latvijas Organiskas Sintezes Instituts €499,654
Liverpool John Moores University €500,000
Lunds Universitet €398,210
Medbioinformatics Solutions SL €350,000
Nederlandse Organisatie Voor Toegepast Natuurwetenschappelijk Onderzoek TNO €366,403
PNO Innovation €862,500
Rijksinstituut Voor Volksgezondheid EN Milieu €929,043
Rise Research Institutes OF Sweden AB €403,348
Signatope GmbH €628,713
Steinbeis GmbH & Co. KG FUR Technologie Transfer €695,000
Stichting VU €813,930
Tissuse GmbH €650,000
Toxys B.V. €259,375
Unilever U.K. Central Resources Ltd. €43,875
Universidad Pompeu Fabra €380,000
Universitair Medisch Centrum Utrecht €339,260
Universitat Konstanz €1,004,000
Universitat Wien €696,750
Universiteit Leiden €2,916,214
Uppsala Universitet €815,755

Source: https://cordis.europa.eu/project/id/964537

The filing refers to a past date, and does not necessarily reflect the current state.